{"title":"Thrombolytic therapy for acute proximal pulmonary embolism without significant haemodynamic compromise","authors":"Brendan P. Madden, Abhijat Sheth, Timothy B.L. Ho","doi":"10.1016/j.rmedx.2005.11.003","DOIUrl":null,"url":null,"abstract":"<div><p><span>Thrombolysis<span> is indicated for patients with massive pulmonary embolism<span> who are haemodynamically unstable. [ACCP Consensus Committee on Pulmonary Embolism. Opinions regarding the diagnosis and management of venous thrombo embolic disease. </span></span></span><em>Chest</em> 1996; <strong>109</strong><span><span>:233–7; Goldhaber SZ, Haire WD, Feldstein ML, Miller M, Toltsiz R, Smith JL, et al. Alteplase<span> versus heparin in acute pulmonary embolism: randomised trial assessing </span></span>right ventricular function and pulmonary perfusion. </span><em>Lancet</em> 1993; <strong>341</strong><span>:507–11] Its use in the management of patients who have proximal life threatening thrombus in the pulmonary vasculature without systemic hypotension is controversial [ACCP Consensus Committee on Pulmonary Embolism. Opinions regarding the diagnosis and management of venous thrombo embolic disease. </span><em>Chest</em> 1996; <strong>109</strong>:233–7; Goldhaber SZ, Haire WD, Feldstein ML, Miller M, Toltsiz R, Smith JL, et al. Alteplase versus heparin in acute pulmonary embolism: randomised trial assessing right ventricular function and pulmonary perfusion. <em>Lancet</em> 1993; <strong>341</strong><span>:507–11]. We describe three patients (two males aged 45 and 58 years) and one female (aged 44 years who was 25 weeks pregnant) with acute proximal pulmonary arterial embolism<span><span> in the absence of systemic hypotension. Surgical embolectomy was considered but our clinical assessment was that the location and extent of the thrombus in each case justified thrombolytic therapy and subsequently </span>heparinisation<span> even though no patient had evidence of systemic hypotension. Each patient was successfully treated with streptokinase (250,000</span></span></span> <!-->iu intravenously over 30<!--> <!-->min followed by 100,000<!--> <!-->iu per h intravenously for 12–24<!--> <span><span><span>h). Warfarin was commenced in two patients to achieve a target INR of 3–4 and low molecular weight heparin was continued throughout the remainder of her pregnancy in the third patient. Follow-up </span>pulmonary angiography<span> showed complete resolution of thrombus and there was improvement in 2D echocardiographic appearance. The pregnant lady delivered a healthy baby, normally, at term. In one patient who is now 6 months post-thrombolysis, repeat estimate of pulmonary vascular resistance and 2D </span></span>echocardiography was normal at 6 months. We suggest that patients with potentially fatal pulmonary emboli should be considered for thrombolytic therapy even if they do not demonstrate haemodynamic instability.</span></p></div>","PeriodicalId":101082,"journal":{"name":"Respiratory Medicine Extra","volume":"2 1","pages":"Pages 34-38"},"PeriodicalIF":0.0000,"publicationDate":"2006-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.rmedx.2005.11.003","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Respiratory Medicine Extra","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1744904905000561","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Thrombolysis is indicated for patients with massive pulmonary embolism who are haemodynamically unstable. [ACCP Consensus Committee on Pulmonary Embolism. Opinions regarding the diagnosis and management of venous thrombo embolic disease. Chest 1996; 109:233–7; Goldhaber SZ, Haire WD, Feldstein ML, Miller M, Toltsiz R, Smith JL, et al. Alteplase versus heparin in acute pulmonary embolism: randomised trial assessing right ventricular function and pulmonary perfusion. Lancet 1993; 341:507–11] Its use in the management of patients who have proximal life threatening thrombus in the pulmonary vasculature without systemic hypotension is controversial [ACCP Consensus Committee on Pulmonary Embolism. Opinions regarding the diagnosis and management of venous thrombo embolic disease. Chest 1996; 109:233–7; Goldhaber SZ, Haire WD, Feldstein ML, Miller M, Toltsiz R, Smith JL, et al. Alteplase versus heparin in acute pulmonary embolism: randomised trial assessing right ventricular function and pulmonary perfusion. Lancet 1993; 341:507–11]. We describe three patients (two males aged 45 and 58 years) and one female (aged 44 years who was 25 weeks pregnant) with acute proximal pulmonary arterial embolism in the absence of systemic hypotension. Surgical embolectomy was considered but our clinical assessment was that the location and extent of the thrombus in each case justified thrombolytic therapy and subsequently heparinisation even though no patient had evidence of systemic hypotension. Each patient was successfully treated with streptokinase (250,000 iu intravenously over 30 min followed by 100,000 iu per h intravenously for 12–24 h). Warfarin was commenced in two patients to achieve a target INR of 3–4 and low molecular weight heparin was continued throughout the remainder of her pregnancy in the third patient. Follow-up pulmonary angiography showed complete resolution of thrombus and there was improvement in 2D echocardiographic appearance. The pregnant lady delivered a healthy baby, normally, at term. In one patient who is now 6 months post-thrombolysis, repeat estimate of pulmonary vascular resistance and 2D echocardiography was normal at 6 months. We suggest that patients with potentially fatal pulmonary emboli should be considered for thrombolytic therapy even if they do not demonstrate haemodynamic instability.
溶栓适用于血流动力学不稳定的大面积肺栓塞患者。[ACCP肺栓塞共识委员会]静脉血栓栓塞性疾病的诊断和治疗意见。胸部1996;109:233-7;Goldhaber SZ, Haire WD, Feldstein ML, Miller M, Toltsiz R, Smith JL,等。阿替普酶与肝素治疗急性肺栓塞:评估右心室功能和肺灌注的随机试验。《柳叶刀》1993年;[341:507-11]它在无全身性低血压的肺血管近端危及生命的血栓患者的治疗中存在争议[ACCP肺栓塞共识委员会]。静脉血栓栓塞性疾病的诊断和治疗意见。胸部1996;109:233-7;Goldhaber SZ, Haire WD, Feldstein ML, Miller M, Toltsiz R, Smith JL,等。阿替普酶与肝素治疗急性肺栓塞:评估右心室功能和肺灌注的随机试验。《柳叶刀》1993年;341:507-11]。我们描述了三名患者(两名男性,年龄分别为45岁和58岁)和一名女性(44岁,怀孕25周)在没有全身性低血压的情况下急性肺动脉近端栓塞。我们考虑过手术栓塞切除术,但我们的临床评估是,每个病例的血栓的位置和范围证明了溶栓治疗和随后的肝素化治疗是合理的,即使没有患者有全体性低血压的证据。每名患者都成功地接受了链激酶治疗(30分钟内静脉注射250,000 iu,随后静脉注射100,000 iu,持续12-24小时)。两名患者开始使用华法林以达到目标INR为3-4,第三名患者在妊娠剩余时间内继续使用低分子量肝素。随访肺动脉造影显示血栓完全消退,二维超声心动图表现改善。这位孕妇正常地足月生下了一个健康的婴儿。在一例溶栓后6个月的患者中,重复估计肺血管阻力和二维超声心动图在6个月时正常。我们建议有潜在致命性肺栓塞的患者应考虑溶栓治疗,即使他们没有表现出血流动力学不稳定。